Skip to main content
. 2016 Jun 21;14(2):1475–1482. doi: 10.3892/mmr.2016.5419

Figure 3.

Figure 3

SDF-1/CXCR4 signaling pathway regulates MMP-13 expression and activity. (A) SDF-1 induced MMP-13 activity in a dose-dependent manner. Cells were treated with SDF-1 in serial dosages of 10, 20, 40 and 80 ng/ml for two days and the conditioned media were collected for ELISA analysis. The increasing SDF-1 effect reached its highest point at the dosage of 40 ng/ml. *P<0.05 vs. control; #P<0.05 vs. cells treated with 40 ng/ml SDF-1; aP<0.05 vs. cells treated with 10 ng/ml SDF-1; bP<0.05 vs. cells treated with 20 ng/ml SDF-1; cP<0.05 vs. cells treated with 80 ng/ml SDF-1. (B) Reverse transcription-quantitative polymerase chain reaction analysis of MMP-13 expression in osteoarthritis chondrocytes treated with SDF-1. SDF-1 significantly increased MMP-13 mRNA expression level in cells (P=0.009), which was significantly reduced by blocking the SDF-1 pathway with AMD 3100 (P=0.001). (C) ELISA analysis of enzyme activity of MMP-13 within conditioned media. SDF-1 significantly increased the activity of MMP-13 (P=0.013), while a significant suppression of MMP-13 activity was observed by blocking the SDF-1 pathway with AMD 3100 (P=0.001). SDF-1, stromal cell-derived factor-1; CXCR4, C-X-C chemokine receptor type 4; MMP-13, matrix metalloproteinase 13.